Improving efficacy of cancer therapy
Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.
1. A method for increasing the efficacy of an anti-cancer treatment in a patient in need thereof, the method comprising administering a TRPV4 agonist or a vector comprising a DNA sequence encoding a human TRVP4 to the patient concurrently with a cancer treatment or subsequently administering the cancer treatment to the patient, wherein the TRPV4 agonist is selected from a group consisting of GSK1016790A, Bisandrographolide A (BAA), RN 1747, AB1644034, α-phorbol 12,13-didecanoate (4αPDD) 5,6-EET, acetylcholine and App441-1.
2. A method for cancer treatment in a patient in need thereof, the method comprising administering a TRPV4 agonist or a vector comprising a DNA sequence encoding a human TRVP4 to the patient concurrently with a cancer treatment or subsequently administering the cancer treatment to the patient, wherein the TRPV4 agonist is selected from a group consisting of GSK1016790A, Bisandrographolide A (BAA), RN 1747, AB1644034, α-phorbol 12,13-didecanoate (4αPDD) 5,6-EET, acetylcholine and App441-1.
3. The method of claim 1 , wherein the cancer treatment is chemotherapy, radiation therapy or immunotherapy.
4. The method of claim 1 , wherein the DNA sequence encoding the human TRVP4 is SEQ. ID. NO. 3, 4 or 5.
5. The method of claim 2 , wherein the cancer treatment is chemotherapy, radiation therapy or immunotherapy.
6. The method of claim 2 , wherein the DNA sequence encoding the human TRVP4 is SEQ. ID. NO. 3, 4 or 5.